Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H26N2O4S.C4H6O5 |
Molecular Weight | 548.605 |
Optical Activity | ( + ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H](CC(O)=O)C(O)=O.COC1=CC=C(C=C1)[C@@H]2SC3=CC=CC=C3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O
InChI
InChIKey=IUSFTUWHKCSCDY-QTKZZPNDSA-N
InChI=1S/C22H26N2O4S.C4H6O5/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3;5-2(4(8)9)1-3(6)7/h5-12,20-21H,13-14H2,1-4H3;2,5H,1H2,(H,6,7)(H,8,9)/t20-,21+;2-/m10/s1
Molecular Formula | C22H26N2O4S |
Molecular Weight | 414.518 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C4H6O5 |
Molecular Weight | 134.0874 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Diltiazem is a nondihydropyridines calcium channel blocker used in the treatment of hypertension, angina pectoris, and some types of arrhythmia. Diltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 |
21.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARDIZEM Approved UseDiltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. The magnitude of blood pressure reduction is related to the degree of hypertension; thus hypertensive individuals experience an antihypertensive effect, whereas there is only a modest fall in blood pressure in normotensives. Launch Date1982 |
|||
Primary | CARDIZEM Approved UseDiltiazem has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic blood pressure at submaximal and maximal work loads. Diltiazem has been shown to be a potent dilator of coronary arteries, both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasm are inhibited by diltiazem. Launch Date1982 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
166.4 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11329099 |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DILTIAZEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2410 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11329099 |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DILTIAZEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.5 h |
360 mg single, oral dose: 360 mg route of administration: Oral experiment type: SINGLE co-administered: |
DILTIAZEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25% |
360 mg single, oral dose: 360 mg route of administration: Oral experiment type: SINGLE co-administered: |
DILTIAZEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
weak | ||||
yes [IC50 0.6 uM] | ||||
yes [IC50 11 uM] | ||||
yes [IC50 120 uM] | yes (co-administration study) Comment: Diltiazem is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some statins. |
|||
yes [Ki 117 uM] | ||||
yes [Ki 12.5 uM] | ||||
yes [Ki 77.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
no | no (pharmacogenomic study) Comment: results suggest that CYP3A5*3 has only a minor effect on the pharmacokinetics and metabolism of diltiazem Sources: https://pubmed.ncbi.nlm.nih.gov/16024008/ |
|||
yes | ||||
yes | ||||
yes | weak (pharmacogenomic study) Comment: Two of the most frequent alleles, CYP3A5 3 and CYP2D6 10, among Chinese do not have major impacts on the disposition of diltiazem and N-desmethyl diltiazem. However, the desacetyl diltiazem showed 2-fold accumulation in individuals with CYP2D6 10/10 genotype |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Improved efficacy and safety of controlled-release diltiazem compared to nifedipine may be related to its negative chronotropic effect. | 2000 Jan |
|
Physiology in medicine: importance of hypoxic pulmonary vasoconstriction in maintaining arterial oxygenation during acute respiratory failure. | 2001 |
|
[Dilren efficacy in postmyocardial infarction patients]. | 2001 |
|
[Unexpected formation of spiro(benzofuran-2,2'-(1,4)benzothiazines) from aurones]. | 2001 Apr |
|
Atrial fibrillation: is rate stabilization a valid clinical strategy? | 2001 Apr |
|
Topical diltiazem ointment in the treatment of chronic anal fissure. | 2001 Apr |
|
An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. | 2001 Apr |
|
Voltage-dependent calcium channels in the rat retina: involvement in NMDA-stimulated influx of calcium. | 2001 Apr |
|
Contribution of amiloride-insensitive pathways to alveolar fluid clearance in adult rats. | 2001 Apr |
|
Atrial fibrillation control and cardioversion. | 2001 Apr 7 |
|
Hexarelin, but not growth hormone, protects heart from damage induced in vitro by calcium deprivation replenishment. | 2001 Feb |
|
Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case. | 2001 Feb |
|
The protective effects of high dose ascorbic acid and diltiazem on myocardial ischaemia-reperfusion injury. | 2001 Feb |
|
Endothelin-1 enhances eicosanoids-induced coronary smooth muscle contraction by activating specific protein kinase C isoforms. | 2001 Feb |
|
Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. | 2001 Feb |
|
Diltiazem-associated photodistributed hyperpigmentation: a review of 4 cases. | 2001 Feb |
|
Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa. | 2001 Feb 25 |
|
Pharmacological interventions of cyanide-induced cytotoxicity and DNA damage in isolated rat thymocytes and their protective efficacy in vivo. | 2001 Feb 3 |
|
Diltiazem affects human dendritic cell maturation. | 2001 Feb-Mar |
|
Diltiazem for nocturnal leg cramps. | 2001 Jan |
|
Muscarinic activation of transient inward current and contraction in canine colon circular smooth muscle cells. | 2001 Jan |
|
Silent ischemic interval on exercise test is a predictor of response to drug therapy: a randomized crossover trial of metoprolol versus diltiazem in stable angina. | 2001 Jan |
|
Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. | 2001 Jan |
|
Design and evaluation of microcapsules of diltiazem hydrochloride. | 2001 Jan-Feb |
|
[Parkinson syndrome from diltiazem]. | 2001 Jan-Feb |
|
Na+ effects on mitochondrial respiration and oxidative phosphorylation in diabetic hearts. | 2001 Jun |
|
Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. | 2001 Jun |
|
Electrophysiological characteristics of rat gustatory cyclic nucleotide--gated channel expressed in Xenopus oocytes. | 2001 Jun |
|
Photostability and phototoxicity studies on diltiazem. | 2001 Jun |
|
Analysis of multicomponent formulations containing phenylpropanolamine hydrochloride, caffeine and diazepam by using LC. | 2001 Jun |
|
Adsorptive stripping voltammetric determination of antihypertensive agent: diltiazem. | 2001 Jun |
|
Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. | 2001 Jun |
|
Positive and negative contractile effects of somatostatin-14 on rat ventricular cardiomyocytes. | 2001 Mar |
|
Effect of angiotensin II on venodilator response to nitroglycerin. | 2001 Mar |
|
Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. | 2001 Mar |
|
Effect of magnesium stearate or calcium stearate as additives on dissolution profiles of diltiazem hydrochloride from press-coated tablets with hydroxypropylmethylcellulose acetate succinate in the outer shell. | 2001 Mar 23 |
|
Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. | 2001 May |
|
Inhibitory effects of TA-993 and its metabolite MB3 on platelet activation induced by collagen and U-46619 in human platelets. | 2001 May |
|
Dilitiazem reduces nitric oxide production by human immune cells. | 2001 May |
|
Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacological Intervention in Atrial Fibrillation Trial (PIAF). | 2001 May |
|
Diltiazem treatment does not alter renal function after thoracic surgery. | 2001 May |
|
Calcium-channel antagonists and nitrates in coronary artery bypass patients receiving radial artery grafts. | 2001 May |
|
Trimetazidine for stable angina pectoris. | 2001 May |
|
Ca2+-dependent exocytosis of L-glutamate by alphaTC6, clonal mouse pancreatic alpha-cells. | 2001 May |
|
Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons. | 2001 May |
|
Calcium-dependent effects of melatonin inhibition of glutamatergic response in rat striatum. | 2001 May |
|
Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. | 2001 May |
|
[Attempted suicide with sustained release diltiazem]. | 2001 May 12 |
|
Characterization of drug release from diltiazem-loaded polylactide microspheres prepared using sodium caseinate and whey protein as emulsifying agents. | 2001 May-Jun |
|
Study of processing parameters influencing the properties of diltiazem hydrochloride microspheres. | 2001 May-Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/dilt-cd.html
When used as monotherapy, reasonable starting doses are 180 to 240 mg once daily, although some patients may respond to lower doses. Maximum antihypertensive effect is usually observed by 14 days of chronic therapy; therefore, dosage adjustments should be scheduled accordingly. The usual dosage range studied in clinical trials was 240 to 360 mg once daily. Individual patients may respond to higher doses of up to 480 mg once daily. Dosages for the treatment of angina should be adjusted to each patient's needs, starting with a dose of 120 or 180 mg once daily. Individual patients may respond to higher doses of up to 480 mg once daily. When necessary, titration may be carried out over a 7- to 14-day period.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7473567
Tissue homogenate of cerebral cortext and heart containing calcium channel receptors was used in a radioligand-binding assays. Cerebral cortices of male SD rats were homogenized. Hearts were also removed, perfused through aorta with ice-cold saline solution, and homogenized. Subsequently, the cardiac homogenates were filtered through four layers of cloth. Both cortical and cardiac homogenates were washed 5 times by centrifugation for 10 min at 48000 g. The final pelle was resuspended to a conc. of 50 mg of original wet tissue wt/mL of buffer and stored at -70°C. Tissue homogenate (200 uL) was incubated for 90 min in a dark room at 0°C with 100 uL of [3H]nitreddipine (3x10^-10M, 87 Ci/mmol) and 100 uL of the test compound dissolved in DMSO in 50 mM of Na-Hepes buffer, pH 7.4. The incubations were stopped by adding 4 mL of cold buffer followed by rapid filtratoin through glass fiber filter disks. The samples were subsequently washed 3 times with 4.5 mL of the same buffer and placed into scintill. vials. Diltiazem inhibited binding of [3H]nitrendipine with Ki of 21 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:01:18 GMT 2025
by
admin
on
Mon Mar 31 18:01:18 GMT 2025
|
Record UNII |
14Y6444DRP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Mon Mar 31 18:01:19 GMT 2025 , Edited by admin on Mon Mar 31 18:01:19 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT001394
Created by
admin on Mon Mar 31 18:01:19 GMT 2025 , Edited by admin on Mon Mar 31 18:01:19 GMT 2025
|
PRIMARY | |||
|
DTXSID00860484
Created by
admin on Mon Mar 31 18:01:19 GMT 2025 , Edited by admin on Mon Mar 31 18:01:19 GMT 2025
|
PRIMARY | |||
|
SUB20629
Created by
admin on Mon Mar 31 18:01:18 GMT 2025 , Edited by admin on Mon Mar 31 18:01:18 GMT 2025
|
PRIMARY | |||
|
FF-28
Created by
admin on Mon Mar 31 18:01:19 GMT 2025 , Edited by admin on Mon Mar 31 18:01:19 GMT 2025
|
PRIMARY | |||
|
14Y6444DRP
Created by
admin on Mon Mar 31 18:01:19 GMT 2025 , Edited by admin on Mon Mar 31 18:01:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL23
Created by
admin on Mon Mar 31 18:01:18 GMT 2025 , Edited by admin on Mon Mar 31 18:01:18 GMT 2025
|
PRIMARY | |||
|
100000086196
Created by
admin on Mon Mar 31 18:01:19 GMT 2025 , Edited by admin on Mon Mar 31 18:01:19 GMT 2025
|
PRIMARY | |||
|
C47493
Created by
admin on Mon Mar 31 18:01:18 GMT 2025 , Edited by admin on Mon Mar 31 18:01:18 GMT 2025
|
PRIMARY | |||
|
144604-00-2
Created by
admin on Mon Mar 31 18:01:18 GMT 2025 , Edited by admin on Mon Mar 31 18:01:18 GMT 2025
|
PRIMARY | |||
|
3037122
Created by
admin on Mon Mar 31 18:01:19 GMT 2025 , Edited by admin on Mon Mar 31 18:01:19 GMT 2025
|
PRIMARY | |||
|
81999
Created by
admin on Mon Mar 31 18:01:18 GMT 2025 , Edited by admin on Mon Mar 31 18:01:18 GMT 2025
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|